BKM120 in Cancers With PIK3CA Activating Mutations

Inclusion Criteria: * At least 1 site of measurable disease * Life expectancy \>/= 12 weeks * Adequate marrow and organ function * Diagnosis of lung cancer, breast cancer, colorectal cancer, cholangiocarcinoma, gastric cancer, pancreatic cancer, prostate cancer, uterine cancer, ovarian cancer, esophageal cancer, or head and neck cancer * Pathologically documented, definitively diagnosed, advanced solid tuor that is refractory to standard treatment, for which no standard therapy is available, or the subject refuses standard therapy * Cancer must have at least one of the following PIK3CA mutations: E542K, E545K, H1047R, H1047L. The PIK3CA mutation must be documented in a CLIA approved laboratory Exclusion Criteria: * Prior treatment with a P13K inhibitor * Known hypersensitivity to BKM120 or its excipients * Untreated brain metastases * Acute or chronic liver, renal disease or pancreatitis * Currently treated with drugs known to be moderate and strong inhibitors or inducers of isoenzyme CYP3A * Diarrhea \>/= CTCAE grade 2 * Any concurrent severe and/or uncontrolled medical condition * Active cardiac disease * History of cardiac dysfunction * Poorly controlled diabetes mellitus or steroid-induced diabetes mellitus * Significant symptomatic deterioration of lung function * Impairment of gastrointestinal (GI) function or GI disease that may significantly alter the absorption of BKDM120 (e.g., ulcerative diseases, uncontrolled nausea, vomiting, diarrhea, malabsorption syndrome, or small bowel resection) * Currently taking therapeutic doses of warfarin sodium or any other coumadin-derivative anticoagulant * Pregnant or breast-feeding * Known diagnosis of HIV infection * History of another malignancy within 3 years, except cured basal cell carcinoma of the skin or excised carcinoma in situ of the cervix * Unable to swallow the medication in its prescribed form